ITeos Therapeutics prices IPO at $19

Oncology biotech, iTeos Therapeutics (ITOS) has priced its IPO of 10,586,316 shares of common stock at $19.00/share (above range of $16-18), for expected gross proceeds of ~$201.1M.

Underwriters’ over-allotment is an additional 1,587,947 shares.

Trading kicks off today. Closing date is July 28.

https://seekingalpha.com/news/3594635-iteos-therapeutics-prices-ipo-19

Nurix Therapeutics prices upsized IPO at $19

Nurix Therapeutics (NRIX) has priced its upsized IPO of 11M (from 8.8M) common shares at $19.00/share (above range from $17- 18), for expected gross proceeds of $209M.

Underwriters’ over-allotment is an additional 1.65M shares.

Trading kicks off today. Closing date is July 28.

Previously: Nurix Therapeutics files for IPO. (July 2)

https://seekingalpha.com/news/3594644-nurix-therapeutics-prices-upsized-ipo-19

Annexon pricing IPO above range at $17

Degenerative disease biotech Annexon Biosciences (ANNX) has priced its IPO of 14.75M common shares at $17.00/share (above range of $14-16), for expected gross proceeds of ~$250.8M.

Underwriters’ over-allotment is an additional 2,212,500 shares.

Trading kicks off today. Closing date is July 28.

Previously: Annexon sets IPO terms (July 20)

https://seekingalpha.com/news/3594652-annexon-pricing-ipo-above-range-17

MyoKardia med nabs accelerated review in thickened heart muscle disorder

The FDA has designated MyoKardia’s (NASDAQ:MYOK) mavacamten a Breakthrough Therapy for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, a disorder characterized by abnormally thick heart muscle that compromises its pumping ability.

Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.

https://seekingalpha.com/news/3594568-myokardias-mavacamten-nabs-accelerated-review-in-u-s-for-thickened-heart-muscle-disorder

Walmart turns up health moves with plans for six more Atlanta clinics

Walmart (NYSE:WMT) says it plans to open at least six more Walmart Health clinics in greater Atlanta by the end of this year – making for a quick tripling of its current clinics, as its strategy to become a healthcare player takes shape, CNBC reports.

That follows quickly on news that Walmart Health would enter the Florida market next year, starting in Jacksonville.

The retail giant currently has four clinics (three in Georgia and one in Springdale, Ark.); it’s targeting 13 by year-end.

Last fall Walmart opened its clinics offering such services as annual checkups, X-rays, hearing checks and mental health counseling, and it already has pharmacies and optical centers in many stores.

And it could consider using perks to boost the healthcare push, CNBC notes: Building its Amazon Prime rival Walmart Plus could offer benefits, considering the company has relationships with several telemedicine companies.

https://seekingalpha.com/news/3594610-walmart-turns-up-health-moves-plans-for-six-atlanta-clinics

Novavax inks manufacturing deal for COVID-19 vaccine

Novavax (NASDAQ:NVAX) enters into an agreement with CDMO FUJIFILM Diosynth Biotechnologies for the manufacture of bulk drug substance for NVX-CoV2373, its COVID-19 vaccine candidate.

Production of the first batch is underway at FUJIFILM’s Morrisville, NC site which is earmarked for a 30K-subject Phase 3 clinical trial expected to launch in the fall.

Manufacturing costs will be funded under the $1.6B award from the U.S. government’s Operation Warp Speed initiative.

Results from a Phase 1 trial in 130 healthy volunteers will be released during the first week of August. The Phase 2 portion will begin shortly thereafter.

https://seekingalpha.com/news/3594527-novavax-inks-manufacturing-deal-for-covidminus-19-vaccine

Edwards Lifesciences EPS beats by $0.15, beats on revenue

Edwards Lifesciences (NYSE:EW): Q2 Non-GAAP EPS of $0.34 beats by $0.15; GAAP EPS of -$0.20 beats by $0.10.

Revenue of $925M (-15.1% Y/Y) beats by $133.29M.

FY20 adjusted EPS guidance increased: $1.75-$1.95 from $1.58-$1.75 earlier.

Press Release

https://seekingalpha.com/news/3594507-edwards-lifesciences-eps-beats-0_15-beats-on-revenue